Actively Recruiting
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Led by AstraZeneca · Updated on 2026-04-27
12
Participants Needed
2
Research Sites
59 weeks
Total Duration
On this page
Sponsors
A
AstraZeneca
Lead Sponsor
C
CTC Clinical Trial Consultants AB
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a phase 1, open-label, PET trial. The study is designed to investigate the effect of AZD2389 on FAP occupancy in the liver in participants with advanced liver fibrosis.
CONDITIONS
Official Title
The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female (non-childbearing potential) aged 20 years or older and able to give written informed consent
- History confirming compensated liver cirrhosis
- Females must have a negative pregnancy test
- Males must use barrier contraceptives
You will not qualify if you...
- Any condition interfering with trial evaluation or participant safety
- Significant illness, major surgery, or trauma before randomization
- Infection with hepatitis B, hepatitis C, or HIV
- Significant liver blood test elevations, MELD score over 12, or platelets below 100 x10^9/L
- Estimated glomerular filtration rate below 60 ml/min/1.73 m2
- History of decompensated liver cirrhosis
- Liver cirrhosis causes that may affect PET signal uptake
- History of bleeding disorders or major bleeding risk
- History of severe skin disorders or poor wound healing
- Positive screening for drugs of abuse or alcohol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Research Site
Solna, Sweden, 171 64
Withdrawn
2
Research Site
Stockholm, Sweden, 17176
Actively Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here